Light-Activated implant could revolutionize arm fracture repair
NCT ID NCT02394080
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study tests a new device called the Photodynamic Bone Stabilization System for treating fractures of the humerus (the upper arm bone). The device is inserted into the bone and hardened with light to hold the broken pieces in place. Researchers are checking how well it helps bones heal and align properly in adults aged 50 and older with acute humerus fractures.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a photodynamic bone stabilization system (a device that uses light to harden a stabilizing material inside the bone)
- What this could lead to
- If successful, this device could offer a less invasive way to stabilize humerus fractures, potentially leading to faster recovery and fewer complications.
- What could go wrong
- This is a small, early-stage study with only 44 participants, so results may not apply to everyone. Risks include infection, device failure, or incomplete bone healing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
44 people
The number who actually took part.
- Start date
-
Feb 2015
- Finished
-
Jan 2018
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Fracture-Specific Inclusion Criteria 1. Radiograph-confirmed diagnosis of acute, single isolated fracture of the humerus. AO classification 11A2, 11A3 and 11B1, 11B2 and 12A1, 12A2, 12A3 and 12B1, 12B2 (The Netherlands); AO Classification 11A1, 11A2, 11A3 and 11B1, 11B2 and 12A1, 12A2, 12A3 and 12B1, 12B2 and 13A1, 13A2 and 13B1, 13B2 (Germany). 2. Fracture is closed, Gustilo Type I or II. General Inclusion Criteria 3. Skeletally mature men and women, 50 years of age or older (The Netherlands only) or 61 years of age or older (Germany only) at time of index injury. 4. a) Female patients of child bearing potential agree to use double barrier method of contraception (The Netherlands only) b) Female patients of non-child bearing potential must meet one of the following criteria (The Netherlands only): * Postmenopausal for at least 1 year, or * Documented oophorectomy or hysterectomy, or * Surgically sterile 5. Willing and able to understand and sign the informed consent. Fracture-Specific Exclusion Criteria 1. Index treatment is greater than 28 days (The Netherlands only) or 14 days (Germany only) post fracture 2. Open fractures with severe contamination. 3. Extremely comminuted fractures where insufficient holding power of the balloon on the intramedullary canal is probable. 4. Marked bone loss or bone resorption patients, who due to a prior delayed union or non-union of the bones or other illnesses, may not be able to have their fracture adequately reduced prior to placement of the IlluminOss-device. This could leave bone void spaces that would preclude the device from maintaining alignment of the fractured bone. 5. Previous fracture of affected limb. General Exclusion Criteria 6. Pregnant or lactating (The Netherlands only). 7. Patients with a contralateral fracture of the forearm or humerus (Germany only). 8. Active or incompletely treated infections that could involve the site where the device will be implanted. 9. Distant foci of infections that may spread to the implant site 10. Uncooperative patients or patients, who are incapable of following directions (for example as a consequence of a neurological or psychiatric disorder). 11. Concomitant metabolic disorders that may impair bone formation. 12. Osteomalacia. 13. Allergic to implant materials or dental glue. 14. Vascular insufficiency, muscular atrophy, or neuro-muscular disease. 15. Polytrauma patients (multiple injuries resulting from a high-impact event, eg- a motor vehicle accident). 16. Life expectancy less than one year due to concurrent illness.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute humerus fractures are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Albert Schweitzer Hospital
Dordrecht, 3318 AT, Netherlands
-
Amphia Hospital
Breda, 4818 CK, Netherlands
-
Klinikum Oberberg GmbH
Gummersbach, 51643, Germany
-
Lahn-Dill Kliniken
Wetzlar, 35578, Germany
-
St. Vinzenz-Hospital GmbH
Cologne, D-50733, Germany
-
University Hospital Maastricht
Maastricht, 6229 HX, Netherlands